German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life Sciences’ research unit, Caris Discovery, to uncover novel oncology targets and develop first-in-class antibody-drug conjugates (ADCs). The partnership aims to harness Caris’ precision medicine expertise and Merck’s ADC technology to accelerate the discovery and development of innovative cancer treatments.
Under the agreement, Caris will receive an upfront payment and research funding, in addition to potential milestone payments of up to USD 1.4 billion and sales royalties. The collaboration will draw on Caris’s advanced AI and machine learning capabilities, extensive tissue repository, molecular profiling technologies, and its proprietary discovery platform to identify and validate new, druggable targets in oncology.
Merck will apply its industry-leading ADC expertise to develop these leads, taking full responsibility for preclinical and clinical research, as well as global commercialization through an exclusive license. This strategic alliance combines Caris’s cutting-edge discovery capabilities with Merck’s development and commercial strengths, positioning the partnership to bring transformative treatments to cancer patients.- Flcube.com
